Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration

Fengfu Li*,1,2, Bernard Hurley1,2, Yun Liu3, Brian Leonard1,2 and May Griffith1,2,4

1Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario K1H8L6, Canada
2University of Ottawa Eye Institute, 501 Smyth Road, Ottawa, Ontario K1H8L6, Canada
3Centre for Catalysis Research and Innovation, and Department of Chemistry, University of Ottawa, 10 Marie Curie, Ottawa, Ontario K1N 6N5, Canada
4Integrative Regenerative Medicine Centre, and Department of Clinical and Experimental Medicine, Linköping University, 581 85 Linköping, Sweden

Abstract: Bevacizumab (Avastin®) has been used by ophthalmologists in many countries as an off-label drug for the treatment of wet age-related macular degeneration (AMD). Due to its short half-life necessitating frequent intravitreal injection, a method for sustained delivery is in need. We demonstrated that bevacizumab could be released in a sustained fashion over 90 days from nano- and microspheres fabricated from poly(DL-lactide-co-glycolide) and poly(ethylene glycol)-b-poly(D,L-lactic acid), respectively. The drug release rate could be adjusted by alteration of the drug/polymer ratio. The use of such nano- and microspheres as bevacizumab delivery vehicles may improve the treatment of wet AMD.

Keywords: Bevacizumab, age-related macular degeneration, nanospheres, microspheres, and controlled release.

1. INTRODUCTION

In the past few years, intravitreal injection of an anti-cancer drug, bevacizumab (Avastin®, Genentech) [1] has been found to be a very effective treatment for the wet form of age-related macular degeneration (AMD) [2], proliferative diabetic retinopathy [3] and choroidal neovascularization [4]. Short-term results suggested that intravitreal bevacizumab (1.25mg) was well tolerated and associated with improvement in visual acuity, decreased retinal thickness and reduction in angiographic leakage in most patients [5]. Bevacizumab is thought to be as safe as ranibizumab (Lucentis®, Genentech), a prescription medication approved for the treatment of wet AMD [6]. It has been increasingly used in many countries as an off-label treatment for AMD and is evolving into the standard of care for wet AMD. However, to achieve and maintain the improvement in vision, repetitive injection and follow-up visits are required. Intravitreal injection is a currently accepted therapy for many posterior segment ocular disorders. However, when repeated injections are required, there is a high risk of complications such as endophthalmitis [7], as well as repetitive pain, apprehension and distress associated with inserting needles into eyes. Moreover, the intravitreal half-life of 1.25mg injected bevacizumab is approximately only 3 days [8]. Therefore an effective drug delivery method needs to be developed to render bevacizumab delivery less invasive and long-lasting.

Recently, nanospheres, microspheres and liposomes have been extensively studied as drug carriers in the pharmaceutical and medical fields [9-14]. They have shown promise as drug delivery systems due to their controlled and sustained release properties, subcellular size and biocompatibility with tissue and cells. Very recently, studies have shown the beneficial effects of liposomes in prolonging the residency of bevacizumab in the vitreous in animal model during 42 days [15]. Hao et al. [16] encapsulated bevacizumab within Poly(DL-lactide-co-glycolide) (PLGA) nanoparticles with an entrapment rate of 45%. The release of the entrapped bevacizumab from the nanoparticles could last 4 weeks. Pan et al. [17] also created long-lasting formulations (8 weeks) of bevacizumab through poly(ethylene glycol) (PEG) conjugation or encapsulation within PLGA nanoparticles. In this study, we encapsulated bevacizumab within particles of PLGA and poly(ethylene glycol)-b-poly(D,L-lactic acid) (PEG-b-PLA), and studied the profiles of drug release from these different polymers.

2. MATERIALS AND METHODS

2.1. Materials

Bevacizumab (25mg/ml, Avastin®, Genentech Inc) was purchased from the Ottawa Hospital Pharmacy (Ottawa, Canada). Poly (DL-lactide-co-glycolide) (50:50) (PLGA, Mw=17,000-22,000Da), PEG(1000)-b-PLA(5000) (PEGLA 15) and PEG(5000)-b-PLA(5000) (PEGLA55) were purchased from PolySciences Inc. (PA, USA).

2.2. Preparation of Bevacizumab-Loaded PLGA Nanoparticles (PLGA-A)

305.2mg PLGA was dissolved in 5ml of dichloromethane. To this solution, 0.2ml of bevacizumab (25mg/ml) was added. The resulting mixture was sonicated for 30 seconds using a probe sonicator (Model VC50, Sonics &
Materials Inc, Danbury, CT, USA). Then, the mixture was poured into 40ml of polyvinylpyrrolidone solution (2.5% w/v) and was sonicated for another 30 seconds. After evaporation of dichloromethane through stirring the mixture overnight in fume hood, nanoparticles were collected through centrifugation and washed with 25ml x 2 MiliQ water. Finally, nanoparticles were freeze-dried overnight, in 74% yield. Bevacizumab loading efficiency (LE) is 95.4% as determined by UV spectrometry based on the following equation:

\[ LE = \frac{C}{C_0} \times 100\% \]

where, C is the quantity of encapsulated bevacizumab - calculated by subtracting the quantity of bevacizumab in the supernatant and the washing solutions from the initial feeding quantity of bevacizumab, C_0.

All other bevacizumab-loaded particles were prepared as described above. For size comparison, bevacizumab-loaded PLGA particles were also prepared by homogenization of the corresponding mixture using a homogenizer (ULTRATURRAX, IKA T10 Basic, IKA Works Inc, USA).

2.3. Bevacizumab Release Study

Between 30-50mg of bevacizumab-loaded particles were placed into centrifuge tubes, followed by addition of 1ml of 10mM phosphate buffered saline (PBS). The tubes were capped and maintained in a 37°C incubator. At certain intervals, the tubes were centrifuged and 0.5ml of the supernatant was removed followed by addition of an equal volume of fresh PBS. The concentration of bevacizumab in the supernatant was determined using a UV spectrophotometer (Beckman 640B) at 270nm against a calibration curve.

3. RESULTS

3.1. Bevacizumab-Loaded Nano- and Microparticles

For equivalent bevacizumab/PLGA ratios (1.6%), the particle size range obtained was dependent upon the method of preparation. PLGA spheres were both obtained but the particle sizes were heterogenous both when a probe sonicator was used (Fig. 1), and when a homogenizer was used (Fig. 2). Sonication resulted in particles with diameters mainly within the 0.2 to 1.0μm range. Particles prepared using a homogenizer, however, were more polydispersed, with the majority of particle diameters ranging from 0.5 to 3μm. When the loading of the drug was increased to bevacizumab/PLGA = 13%, the particles no longer showed shape uniformity, although some spheres were still present (Fig. 3). The particles fabricated from PEGLA15 appeared spherical and porous (Fig. 4), with the diameters of the particles ranging from 2 to 10μm. When PEGLA55 polymer was used, the diameter of particles was under 1μm, but the particles were no longer spherical (Fig. 5).

Within our experimental range, the drug encapsulation (loading) efficiency was above 90% (Table 1) when PLGA and PEGLA15 polymers were used. The yield of the particles was greater than 70% with these two polymers. However, when PEGLA55 was used, the yield dropped to 24%.
3.2. Bevacizumab Release Profiles

For the particles with an initial bevacizumab/PLGA=1.6% loading ratio (PLGA-A, Table 1), approximately 0.5mg of bevacizumab was relatively steadily released over 55 days (Fig. 6). Beyond this time until day 91, only an insignificant amount of release was detected. However, when the bevacizumab/PLGA ratio was increased to 13% (PLGA-HiA, Table 1), a steady release of 1.9mg of bevacizumab was observed throughout the experimental period of 91 days. There was a plateau in the release profile around 30 days for both of the release curves (Figs. 6, 7). Over the 91-day release period, we calculated that approximately 47% and 64% bevacizumab were released from particles with 1.6% and 13% drug loading respectively. Bevacizumab release from the PEGLA15 particles showed a similar plateau in the release profile (Fig. 8) as those in Figs. (6) and (7), but starting at about day 20. Approximately 62% of encapsulated bevacizumab was released from this system during the 91-day period.

Table 1. Drug Encapsulation (Load) Efficiency

| Particle Types | Yield, % | Load Efficiency, % | Drug/Polymer, % | Particle Size, μm |
|----------------|----------|--------------------|-----------------|------------------|
| PLGA-A*        | 74       | 95.4               | 1.6             | 0.2-1            |
| PLGA-HiA       | 80       | 96.4               | 12.9            | < 1              |
| PEG1A5-A       | 99       | 93.6               | 1.9             | 2-10             |
| PEG1A55-A      | 24       | NA                 | 2.0             | <1               |

* represents bevacizumab.
efficiency was only about 45%. Hao et al. [16] also reported a similar drug encapsulation efficiency using ethyl acetate and phosphate buffer as oil and aqueous phases respectively. However, in our approach, more than 90% drug encapsulation efficiency was achieved via double emulsion methods using PLGA and PEGLA15 polymers.

The plateaus in the release profiles at around 30 days for both of the release curves as shown in Figs. (6) and (7), suggested that the release of the surface absorbed bevacizumab was completed after about 30 days of incubation of the particles. After that, the PLGA began degrading and released additional drug entrapped within the polymeric core [32].

5. CONCLUSION

Our results indicated that bevacizumab can be released from nano- and microparticles of PLGA and PEGLA in a sustained fashion for over 91 days. The release rate could be adjusted by altering the drug/polymer ratio. However, bevacizumab activity still needs to be tested in vivo using animal models. Nevertheless, these results may offer improvements for the treatment of wet AMD using bevacizumab and may also improve cancer treatment using the same carriers for sustained release of the drug.

ACKNOWLEDGEMENT

Declared none.

CONFLICT OF INTEREST

Declared none.

REFERENCES

[1] Ferrara N, Hillan K, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-35.
[2] Michels S, Rosenfeld PJ, Pulahto CA, et al. Systemic bevacizumab (avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2006; 112: 1035-47.
[3] Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113 (10): 1695-705.
[4] Spada RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-90.
[5] Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir AA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
[6] Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007; 85(1): 119-20.
[7] Yenerel NM, Dinc UA, Gorgen E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008; 24(3): 362-3.
[8] Beer PM, Wong SJ, Hammad AM, Fall NS, O’Malley MR. Vitreous levels of bound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006; 26: 871-6.
[9] Xia Y. Nanomaterials at work in biomedical research. Nat Mater 2008; 7(10): 758-60.
[10] Pinto RC, Neufeld RJ, Ribeiro AJ, Veiga F. Nannoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006; 2(1): 8-21.
[11] Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nannoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2006; 2(2): 53-65.
[12] Torchilin VP. Multifunctional nanocarriers. Adv Drug Del Rev 2006; 58(14): 1532-55.
[13] Mainardes RM, Urban MC, Cinto PO, et al. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets 2005; 6(3): 363-71.
[14] Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adams AP. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 2003; 44(1): 290-9.
[15] Abrishami M, Zarei-Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina 2009; 29(5): 699-703.
[16] Hao Y, Patel A, Liu W, Krishna R, Sabates NR, Mitra AK. Preparation and characterization of bevacizumab (avastin) nanoparticles for the treatment of age related macular degeneration. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Los Angeles, California, U.S.A. November, 2009. Available from http://www.aapsj.org/abstracts/AM_2009/AAPS2009-002539.PDF
[17] Pan CK, Durairaj C, Kompella UB, et al. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther 2011; 27: 219-24.
[18] Gopferich A, Langer R. Modeling monomer release from bioerodible polymers. J Control Release 1995; 33: 55-69.
[19] Batycky RP, Hanes J, Langer R, Edwards DA. A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. J Pharm Sci 1997; 86: 1464-77.
[20] Frazza EJ, Schmitt EE. A new absorbable suture. J Biomed Mater Res 1971; 1: 43-58
[21] Hasirci V, Berthiaume F, Bondre SP, et al. Expression of liver-specific functions by rat hepatocytes seeded in treated poly(lactic-co-glycolic) acid biodegradable foams. Tissue Eng 2001; 7: 385-94.
[22] Ma PX, Choi JW. Biodegradable polymer scaffolds with well-defined interconnected spherical pore network. Tissue Eng 2001; 7: 23-33
[23] Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev1997; 28: 5-24.
[24] Jain RA, Rhodes CT, Rainkar AM, Malick AW, Shah NH. Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: Effect of various formulation variables. Eur J Pharm Biopharm 2000, 50(2): 257-62.
[25] Duvvuri S, Janoria KG, Mitra AK. Development of a novel formulation containing poly(D,L-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J Control Release 2005; 108: 282-93.
[26] Xu J, Wang Y, Li Y, et al. Inhibitory Efficacy of Intravitreal Dexamethasone Acetate-Loaded PLGA Nanoparticles on Choroidal Neovascularization in a Laser-Induced Rat Model. J Ocul Pharmacol Ther 2007; 23(6): 527-39.
[27] Duvvuri S, Janoria KG, Pal D, Mitra AK. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(D,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis. J Ocul Pharmacol Ther 2007; 23(3): 264-74.
[28] Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci 1991; 32: 1785-90.
[29] Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis 2007; 13: 1783-92.
[30] Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adams AP. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 2003; 44(1): 290-9.
[31] Giordano GG, Chevez-Barrios P, Refojo MF, Garcia CA. Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolide)acids microspheres. Curr Eye Res 1995; 14(9): 761-8.
[32] Cao X, Schiochet MS. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials 1999; 20(4): 329-39.

Received: June 6, 2012 Revised: June 11, 2012 Accepted: June 11, 2012

© Li et al.; Licensee Bentham Open.
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.